查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1762314

前列腺癌症生物标记市场，规模，占有率，产业分析报告:类别，各用途，各最终用途，各地区，2025年～2034年的市场预测

Prostate Cancer Biomarker Market Size, Share, & Industry Analysis Report: By Type (Genetic Biomarkers, Protein Biomarkers, Cell-Based Biomarkers, and Metabolomic Biomarkers), By Application, By End Use, and By Region - Market Forecast, 2025-2034
出版日期: | 出版商: Polaris Market Research | 英文 129 Pages | 商品交期: 最快1-2个工作天内

价格

根据 Polaris Market Research 的最新研究，前列腺癌生物标记市场规模预计到 2034 年将达到 155.8 亿美元。本研究报告深入分析了当前的市场动态，并分析了未来的市场成长。

前列腺癌生物标记是从体液和组织中提取的分子指标，有助于识别前列腺癌的存在、分期和进展。人工智慧等多组学方法在基因组学、蛋白质组学和代谢组学中的应用，提高了诊断准确性和疾病分层，进一步推动了市场需求。这些广泛的分析技术能够发现具有更高灵敏度和特异性的新型生物标记物，从而支持更准确的患者分类和个人化治疗策略。随着个人化癌症治疗日益受到重视，多组学驱动的生物标记平台在临床和研究环境中的应用正变得越来越重要。

非侵入性和微创诊断技术的进步正在推动市场发展。液体活检因其能够透过血液或尿液样本检测和监测前列腺癌而日益受到关注，为传统组织活检提供了一种更安全、更便捷的替代方案。这些方法提高了患者的依从性，并允许即时监测病情和调整治疗方案。随着医疗保健系统优先考虑早期检测和微创诊断，对此类创新技术的需求也日益增长，这进一步强化了先进生物标记技术在前列腺癌管理转型中的作用。

前列腺癌生物标记市场报告重点

按类型划分，蛋白质生物标记在2024年占据了最大的市场占有率，这得益于其广泛的临床应用以及在多个疾病管理阶段的完善验证。

从应用角度来看，伴随诊断领域预计将以最快的速度成长，这得益于个人化治疗方法和精准医疗的日益普及。

预计到2024年，北美将在前列腺癌生物标记市场中占据最大的收入占有率，这得益于完善的医疗保健体系、日益增长的疾病意识以及诊断和生物製药公司的聚集。

预计亚太市场将在预测期内实现最快的市场成长，这得益于医疗保健知识的提高、市场诊断能力的提升以及新兴国家癌症发病率的上升。

全球主要市场参与者包括Arquer Diagnostics、Beckman Coulter、Bio-Techne、DiaCarta、Exact Sciences Corporation、ExoDx、Genomic Health、GenPath Oncology、MDxHealth、Myriad Genetics、Nucleix、OPKO Health、Proteomedix和Veracyte。

目录

第1章 简介

第2章 摘要整理

第3章 调查手法

第4章 全球前列腺癌症生物标记市场洞察

  • 市场概述
  • 前列腺癌症生物标记市场动态
    • 促进因素和机会
      • 摄护腺癌发生率上升及人口老化
      • 生物标记技术的进步
    • 阻碍因素与课题
      • 生物标记开发和检测成本高昂
    • 公众舆论与隐私案例法
  • PESTEL分析
  • 前列腺癌症生物标记市场趋势
  • 价值链分析

第5章 全球前列腺癌症生物标记市场:类别

  • 主要调查结果
  • 简介
  • 遗传基因生物标记
  • 蛋白质生物标记
  • 细胞为基础的生物标记
  • 代谢体学生物标记

第6章 全球前列腺癌症生物标记市场:各用途

  • 主要调查结果
  • 简介
  • 筛检早与期发现
  • 诊断与风险层化
  • 预后和治疗的监测
  • 伴随式诊断

第7章 全球前列腺癌症生物标记市场:各最终用途

  • 主要调查结果
  • 简介
  • 医院及诊断检验室
  • 学术研究机关
  • 生物医药品企业

第8章 全球前列腺癌症生物标记市场:各地区

  • 主要调查结果
  • 简介
    • 前列腺癌症生物标记市场分析:各地区，2020～2034年
  • 北美
    • 北美:类别，2020～2034年
    • 北美:各用途，2020～2034年
    • 北美:各最终用途，2020～2034年
    • 美国
    • 加拿大
  • 欧洲
    • 欧洲:类别，2020～2034年
    • 欧洲:各用途，2020～2034年
    • 欧洲:各最终用途，2020～2034年
    • 英国
    • 法国
    • 德国
    • 义大利
    • 西班牙
    • 荷兰
    • 俄罗斯
    • 其他欧洲
  • 亚太地区
    • 亚太地区:类别，2020～2034年
    • 亚太地区:各用途，2020～2034年
    • 亚太地区:各最终用途，2020～2034年
    • 中国
    • 印度
    • 马来西亚
    • 日本
    • 印尼
    • 韩国
    • 澳洲
    • 其他亚太地区
  • 中东·非洲
    • 中东·非洲:类别，2020～2034年
    • 中东·非洲:各用途，2020～2034年
    • 中东·非洲:各最终用途，2020～2034年
    • 沙乌地阿拉伯
    • 阿拉伯联合大公国
    • 以色列
    • 南非
    • 其他中东和非洲
  • 南美
    • 南美:类别，2020-2034年
    • 南美:各用途，2020～2034年
    • 南美:各最终用途，2020～2034年
    • 墨西哥
    • 巴西
    • 阿根廷
    • 其他南美国家

第9章 竞争情形

  • 扩大和收购的分析
    • 扩大
    • 收购
  • 联盟/合作/协定/公开

第10章 企业简介

  • AlterG, Inc.
  • Biodex Medical Systems, Inc.
  • Caremax Prostate Cancer Biomarker Ltd.
  • DJO Global
  • Drive DeVilbiss Healthcare
  • Ekso Bionics
  • GF Health Products, Inc.
  • Hocoma AG
  • Hospital Equipment Mfg. Co
  • Invacare Corporation
  • Maddak, Inc.
  • Ottobock
  • Patterson Medical(now Ability Dynamics)
  • Rifton Equipment
  • TheraBand(Performance Health)
Product Code: PM5692

The prostate cancer biomarkers market size is expected to reach USD 15.58 billion by 2034, according to a new study by Polaris Market Research. The report "Prostate Cancer Biomarker Market Share, Size, & Industry Analysis Report: By Type (Genetic Biomarkers, Protein Biomarkers, Cell-Based Biomarkers, and Metabolomic Biomarkers), By application, By End Use, and By Region; Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.

Prostate cancer biomarkers are molecular indicators derived from bodily fluids or tissues that aid in identifying the presence, stage, or progression of prostate cancer. The integration of multi-omics approaches such as AI in genomics, proteomics, and metabolomics to improve diagnostic precision and disease stratification further boosts the market demand. These wide profiling techniques allow the discovery of novel biomarkers with greater sensitivity and specificity, supporting more accurate patient categorization and tailored treatment strategies. The adoption of multi-omics-driven biomarker platforms is becoming increasingly central to clinical and research settings as the focus on individualized cancer care intensifies.

The advancement of noninvasive and minimally invasive diagnostic techniques is boosting the market development. Liquid biopsies are gaining traction for their ability to detect and monitor prostate cancer using blood or urine samples, offering a safer and more convenient alternative to traditional tissue biopsies. These methods improve patient compliance and allow for real-time disease monitoring and therapy adjustment. The demand for such innovations continues to grow as healthcare systems prioritize early detection and less invasive diagnostics, reinforcing the role of advanced biomarker technologies in transforming prostate cancer management.

Prostate Cancer Biomarker Market Report Highlights

In terms of type, the protein biomarkers segment accounted for the largest market share in 2024, supported by their extensive clinical applications and well-established validation across multiple disease management phases.

Based on application, the companion diagnostics segment is anticipated to experience the most rapid expansion, propelled by growing implementation of personalized treatment approaches and precision therapies.

In 2024, North America maintained the largest revenue share of the prostate cancer biomarker market, owing to its sophisticated healthcare systems, elevated disease awareness, and concentration of diagnostic and biopharmaceutical firms.

The Asia Pacific market is projected to achieve the fastest market growth during the forecast period, driven by improving healthcare knowledge, developing diagnostic capabilities, and increasing cancer prevalence in emerging nations.

A few global key market players include Arquer Diagnostics; Beckman Coulter, Inc.; Bio-Techne; DiaCarta; Exact Sciences Corporation; ExoDx; Genomic Health; GenPath Oncology; MDxHealth; Myriad Genetics, Inc.; Nucleix; OPKO Health, Inc.; Proteomedix; and Veracyte, Inc.

Polaris Market Research has segmented the prostate cancer biomarker market report on the basis of type, application, end use, and region:

By Type Outlook (Revenue, USD Billion, 2020-2034)

Genetic Biomarkers

Protein Biomarkers

Cell-based Biomarkers

Metabolomic Biomarkers

By Application Outlook (Revenue, USD Billion, 2020-2034)

Screening and Early Detection

Diagnosis and Risk Stratification

Prognosis and Treatment Monitoring

Companion Diagnostics

By End Use Outlook (Revenue, USD Billion, 2020-2034)

Hospitals & Diagnostic Laboratories

Academic & Research Institutes

Biopharmaceutical Companies

By Regional Outlook (Revenue, USD Billion, 2020-2034)

North America

US

Canada

Europe

Germany

UK

France

Italy

Spain

Russia

Netherlands

Rest of Europe

Asia Pacific

China

India

Japan

South Korea

Indonesia

Malaysia

Vietnam

Australia

Rest of Asia Pacific

Latin America

Argentina

Brazil

Mexico

Rest of Latin America

Middle East & Africa

UAE

Saudi Arabia

Israel

South Africa

Rest of Middle East & Africa

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Prostate Cancer Biomarker Market Insights

  • 4.1. Prostate Cancer Biomarker Market - Market Snapshot
  • 4.2. Prostate Cancer Biomarker Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Rising Prevalence of Prostate Cancer and Aging Populations
      • 4.2.1.2. Advancements in Biomarker Technologies
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. High Cost of Biomarker Development and Testing
    • 4.2.3. Public opinion and privacy legal precedents
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTEL Analysis
  • 4.5. Prostate Cancer Biomarker Market Trends
  • 4.6. Value Chain Analysis

5. Global Prostate Cancer Biomarker Market, by Type

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
  • 5.3. Genetic Biomarkers
    • 5.3.1. Global Prostate Cancer Biomarker Market, by Genetic Biomarkers, by Region, 2020-2034 (USD Billion)
  • 5.4. Protein Biomarkers
    • 5.4.1. Global Prostate Cancer Biomarker Market, by Protein Biomarkers, by Region, 2020-2034 (USD Billion)
  • 5.5. Cell-based Biomarkers
    • 5.5.1. Global Prostate Cancer Biomarker Market, by Cell-based Biomarkers, by Region, 2020-2034 (USD Billion)
  • 5.6. Metabolomic Biomarkers
    • 5.6.1. Global Prostate Cancer Biomarker Market, by Metabolomic Biomarkers, by Region, 2020-2034 (USD Billion)

6. Global Prostate Cancer Biomarker Market, by Application

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
  • 6.3. Screening and Early Detection
    • 6.3.1. Global Prostate Cancer Biomarker Market, by Screening and Early Detection, by Region, 2020-2034 (USD Billion)
  • 6.4. Diagnosis and Risk Stratification
    • 6.4.1. Global Prostate Cancer Biomarker Market, by Diagnosis and Risk Stratification, by Region, 2020-2034 (USD Billion)
  • 6.5. Prognosis and Treatment Monitoring
    • 6.5.1. Global Prostate Cancer Biomarker Market, by B-Arrestin Functional Assays, by Region, 2020-2034 (USD Billion)
  • 6.6. Companion Diagnostics
    • 6.6.1. Global Prostate Cancer Biomarker Market, by Companion Diagnostics, by Region, 2020-2034 (USD Billion)

7. Global Prostate Cancer Biomarker Market, by End Use

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Global Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
  • 7.3. Hospitals & Diagnostic Laboratories
    • 7.3.1. Global Prostate Cancer Biomarker Market, by Hospitals & Diagnostic Laboratories, by Region, 2020-2034 (USD Billion)
  • 7.4. Academic & Research Institutes
    • 7.4.1. Global Prostate Cancer Biomarker Market, by Academic & Research Institutes, by Region, 2020-2034 (USD Billion)
  • 7.5. Biopharmaceutical Companies
    • 7.5.1. Global Prostate Cancer Biomarker Market, by Biopharmaceutical Companies, by Region, 2020-2034 (USD Billion)

8. Global Prostate Cancer Biomarker Market, by Geography

  • 8.1. Key Findings
  • 8.2. Introduction
    • 8.2.1. Prostate Cancer Biomarker Market Assessment, By Geography, 2020-2034 (USD Billion)
  • 8.3. Prostate Cancer Biomarker Market - North America
    • 8.3.1. North America: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
    • 8.3.2. North America: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
    • 8.3.3. North America: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
    • 8.3.4. Prostate Cancer Biomarker Market - US
      • 8.3.4.1. US: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
      • 8.3.4.2. US: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
      • 8.3.4.3. US: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
    • 8.3.5. Prostate Cancer Biomarker Market - Canada
      • 8.3.5.1. Canada: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
      • 8.3.5.2. Canada: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
      • 8.3.5.3. Canada: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
  • 8.4. Prostate Cancer Biomarker Market - Europe
    • 8.4.1. Europe: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
    • 8.4.2. Europe: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
    • 8.4.3. Europe: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
    • 8.4.4. Prostate Cancer Biomarker Market - UK
      • 8.4.4.1. UK: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
      • 8.4.4.2. UK: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
      • 8.4.4.3. UK: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
    • 8.4.5. Prostate Cancer Biomarker Market - France
      • 8.4.5.1. France: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
      • 8.4.5.2. France: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
      • 8.4.5.3. France: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
    • 8.4.6. Prostate Cancer Biomarker Market - Germany
      • 8.4.6.1. Germany: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
      • 8.4.6.2. Germany: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
      • 8.4.6.3. Germany: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
    • 8.4.7. Prostate Cancer Biomarker Market - Italy
      • 8.4.7.1. Italy: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
      • 8.4.7.2. Italy: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
      • 8.4.7.3. Italy: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
    • 8.4.8. Prostate Cancer Biomarker Market - Spain
      • 8.4.8.1. Spain: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
      • 8.4.8.2. Spain: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
      • 8.4.8.3. Spain: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
    • 8.4.9. Prostate Cancer Biomarker Market - Netherlands
      • 8.4.9.1. Netherlands: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
      • 8.4.9.2. Netherlands: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
      • 8.4.9.3. Netherlands: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
    • 8.4.10. Prostate Cancer Biomarker Market - Russia
      • 8.4.10.1. Russia: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
      • 8.4.10.2. Russia: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
      • 8.4.10.3. Russia: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
    • 8.4.11. Prostate Cancer Biomarker Market - Rest of Europe
      • 8.4.11.1. Rest of Europe: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
      • 8.4.11.2. Rest of Europe: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
      • 8.4.11.3. Rest of Europe: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
  • 8.5. Prostate Cancer Biomarker Market - Asia Pacific
    • 8.5.1. Asia Pacific: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
    • 8.5.2. Asia Pacific: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
    • 8.5.3. Asia Pacific: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
    • 8.5.4. Prostate Cancer Biomarker Market - China
      • 8.5.4.1. China: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
      • 8.5.4.2. China: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
      • 8.5.4.3. China: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
    • 8.5.5. Prostate Cancer Biomarker Market - India
      • 8.5.5.1. India: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
      • 8.5.5.2. India: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
      • 8.5.5.3. India: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
    • 8.5.6. Prostate Cancer Biomarker Market - Malaysia
      • 8.5.6.1. Malaysia: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
      • 8.5.6.2. Malaysia: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
      • 8.5.6.3. Malaysia: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
    • 8.5.7. Prostate Cancer Biomarker Market - Japan
      • 8.5.7.1. Japan: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
      • 8.5.7.2. Japan: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
      • 8.5.7.3. Japan: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
    • 8.5.8. Prostate Cancer Biomarker Market - Indonesia
      • 8.5.8.1. Indonesia: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
      • 8.5.8.2. Indonesia: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
      • 8.5.8.3. Indonesia: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
    • 8.5.9. Prostate Cancer Biomarker Market - South Korea
      • 8.5.9.1. South Korea: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
      • 8.5.9.2. South Korea: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
      • 8.5.9.3. South Korea: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
    • 8.5.10. Prostate Cancer Biomarker Market - Australia
      • 8.5.10.1. Australia: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
      • 8.5.10.2. Australia: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
      • 8.5.10.3. Australia: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
    • 8.5.11. Prostate Cancer Biomarker Market - Rest of Asia Pacific
      • 8.5.11.1. Rest of Asia Pacific: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
      • 8.5.11.2. Rest of Asia Pacific: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
      • 8.5.11.3. Rest of Asia Pacific: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
  • 8.6. Prostate Cancer Biomarker Market - Middle East & Africa
    • 8.6.1. Middle East & Africa: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
    • 8.6.2. Middle East & Africa: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
    • 8.6.3. Middle East & Africa: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
    • 8.6.4. Prostate Cancer Biomarker Market - Saudi Arabia
      • 8.6.4.1. Saudi Arabia: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
      • 8.6.4.2. Saudi Arabia: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
      • 8.6.4.3. Saudi Arabia: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
    • 8.6.5. Prostate Cancer Biomarker Market - UAE
      • 8.6.5.1. UAE: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
      • 8.6.5.2. UAE: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
      • 8.6.5.3. UAE: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
    • 8.6.6. Prostate Cancer Biomarker Market - Israel
      • 8.6.6.1. Israel: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
      • 8.6.6.2. Israel: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
      • 8.6.6.3. Israel: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
    • 8.6.7. Prostate Cancer Biomarker Market - South Africa
      • 8.6.7.1. South Africa: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
      • 8.6.7.2. South Africa: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
      • 8.6.7.3. South Africa: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
    • 8.6.8. Prostate Cancer Biomarker Market - Rest of Middle East & Africa
      • 8.6.8.1. Rest of Middle East & Africa: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
      • 8.6.8.2. Rest of Middle East & Africa: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
      • 8.6.8.3. Rest of Middle East & Africa: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
  • 8.7. Prostate Cancer Biomarker Market - Latin America
    • 8.7.1. Latin America: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
    • 8.7.2. Latin America: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
    • 8.7.3. Latin America: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
    • 8.7.4. Prostate Cancer Biomarker Market - Mexico
      • 8.7.4.1. Mexico: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
      • 8.7.4.2. Mexico: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
      • 8.7.4.3. Mexico: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
    • 8.7.5. Prostate Cancer Biomarker Market - Brazil
      • 8.7.5.1. Brazil: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
      • 8.7.5.2. Brazil: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
      • 8.7.5.3. Brazil: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
    • 8.7.6. Prostate Cancer Biomarker Market - Argentina
      • 8.7.6.1. Argentina: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
      • 8.7.6.2. Argentina: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
      • 8.7.6.3. Argentina: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
    • 8.7.7. Prostate Cancer Biomarker Market - Rest of Latin America
      • 8.7.7.1. Rest of Latin America: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
      • 8.7.7.2. Rest of Latin America: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
      • 8.7.7.3. Rest of Latin America: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)

9. Competitive Landscape

  • 9.1. Expansion and Acquisition Analysis
    • 9.1.1. Expansion
    • 9.1.2. Acquisitions
  • 9.2. Partnerships/Collaborations/Agreements/Exhibitions

10. Company Profiles

  • 10.1. AlterG, Inc.
    • 10.1.1. Company Overview
    • 10.1.2. Financial Performance
    • 10.1.3. Product Benchmarking
    • 10.1.4. Recent Development
  • 10.2. Biodex Medical Systems, Inc.
    • 10.2.1. Company Overview
    • 10.2.2. Financial Performance
    • 10.2.3. Product Benchmarking
    • 10.2.4. Recent Development
  • 10.3. Caremax Prostate Cancer Biomarker Ltd.
    • 10.3.1. Company Overview
    • 10.3.2. Financial Performance
    • 10.3.3. Product Benchmarking
    • 10.3.4. Recent Development
  • 10.4. DJO Global
    • 10.4.1. Company Overview
    • 10.4.2. Financial Performance
    • 10.4.3. Product Benchmarking
    • 10.4.4. Recent Development
  • 10.5. Drive DeVilbiss Healthcare
    • 10.5.1. Company Overview
    • 10.5.2. Financial Performance
    • 10.5.3. Product Benchmarking
    • 10.5.4. Recent Development
  • 10.6. Ekso Bionics
    • 10.6.1. Company Overview
    • 10.6.2. Financial Performance
    • 10.6.3. Product Benchmarking
    • 10.6.4. Recent Development
  • 10.7. GF Health Products, Inc.
    • 10.7.1. Company Overview
    • 10.7.2. Financial Performance
    • 10.7.3. Product Benchmarking
    • 10.7.4. Recent Development
  • 10.8. Hocoma AG
    • 10.8.1. Company Overview
    • 10.8.2. Financial Performance
    • 10.8.3. Product Benchmarking
    • 10.8.4. Recent Development
  • 10.9. Hospital Equipment Mfg. Co
    • 10.9.1. Company Overview
    • 10.9.2. Financial Performance
    • 10.9.3. Product Benchmarking
    • 10.9.4. Recent Development
  • 10.10. Invacare Corporation
    • 10.10.1. Company Overview
    • 10.10.2. Financial Performance
    • 10.10.3. Product Benchmarking
    • 10.10.4. Recent Development
  • 10.11. Maddak, Inc.
    • 10.11.1. Company Overview
    • 10.11.2. Financial Performance
    • 10.11.3. Product Benchmarking
    • 10.11.4. Recent Development
  • 10.12. Ottobock
    • 10.12.1. Company Overview
    • 10.12.2. Financial Performance
    • 10.12.3. Product Benchmarking
    • 10.12.4. Recent Development
  • 10.13. Patterson Medical (now Ability Dynamics)
    • 10.13.1. Company Overview
    • 10.13.2. Financial Performance
    • 10.13.3. Product Benchmarking
    • 10.13.4. Recent Development
  • 10.14. Rifton Equipment
    • 10.14.1. Company Overview
    • 10.14.2. Financial Performance
    • 10.14.3. Product Benchmarking
    • 10.14.4. Recent Development
  • 10.15. TheraBand (Performance Health)
    • 10.15.1. Company Overview
    • 10.15.2. Financial Performance
    • 10.15.3. Product Benchmarking
    • 10.15.4. Recent Development

List of Tables:

  • Table 1 Global Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
  • Table 2 Global Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
  • Table 3 Global Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
  • Table 4 North America: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
  • Table 5 North America: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
  • Table 6 North America: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
  • Table 7 US: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
  • Table 8 US: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
  • Table 9 US: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
  • Table 10 Canada: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
  • Table 11 Canada: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
  • Table 12 Canada: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
  • Table 13 Europe: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
  • Table 14 Europe: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
  • Table 15 Europe: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
  • Table 16 UK: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
  • Table 17 UK: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
  • Table 18 UK: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
  • Table 19 France: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
  • Table 20 France: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
  • Table 21 France: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
  • Table 22 Germany: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
  • Table 23 Germany: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
  • Table 24 Germany: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
  • Table 25 Italy: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
  • Table 26 Italy: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
  • Table 27 Italy: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
  • Table 28 Spain: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
  • Table 29 Spain: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
  • Table 30 Spain: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
  • Table 31 Netherlands: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
  • Table 32 Netherlands: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
  • Table 33 Netherlands: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
  • Table 34 Russia: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
  • Table 35 Russia: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
  • Table 36 Russia: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
  • Table 37 Rest of Europe: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
  • Table 38 Rest of Europe: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
  • Table 39 Rest of Europe: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
  • Table 40 Asia Pacific: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
  • Table 41 Asia Pacific: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
  • Table 42 Asia Pacific: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
  • Table 43 China: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
  • Table 44 China: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
  • Table 45 China: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
  • Table 46 India: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
  • Table 47 India: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
  • Table 48 India: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
  • Table 49 Malaysia: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
  • Table 50 Malaysia: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
  • Table 51 Malaysia: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
  • Table 52 Japan: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
  • Table 53 Japan: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
  • Table 54 Japan: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
  • Table 55 Indonesia: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
  • Table 56 Indonesia: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
  • Table 57 Indonesia: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
  • Table 58 South Korea: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
  • Table 59 South Korea: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
  • Table 60 South Korea: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
  • Table 61 Australia: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
  • Table 62 Australia: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
  • Table 63 Australia: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
  • Table 64 Rest of Asia Pacific: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
  • Table 65 Rest of Asia Pacific: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
  • Table 66 Rest of Asia Pacific: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
  • Table 67 Middle East & Africa: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
  • Table 68 Middle East & Africa: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
  • Table 69 Middle East & Africa: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
  • Table 70 Saudi Arabia: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
  • Table 71 Saudi Arabia: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
  • Table 72 Saudi Arabia: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
  • Table 73 UAE: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
  • Table 74 UAE: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
  • Table 75 UAE: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
  • Table 76 Israel: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
  • Table 77 Israel: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
  • Table 78 Israel: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
  • Table 79 South Africa: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
  • Table 80 South Africa: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
  • Table 81 South Africa: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
  • Table 82 Rest of Middle East & Africa: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
  • Table 83 Rest of Middle East & Africa: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
  • Table 84 Rest of Middle East & Africa: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
  • Table 85 Latin America: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
  • Table 86 Latin America: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
  • Table 87 Latin America: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
  • Table 88 Mexico: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
  • Table 89 Mexico: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
  • Table 90 Mexico: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
  • Table 91 Brazil: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
  • Table 92 Brazil: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
  • Table 93 Brazil: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
  • Table 94 Argentina: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
  • Table 95 Argentina: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
  • Table 96 Argentina: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
  • Table 97 Rest of Latin America: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
  • Table 98 Rest of Latin America: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
  • Table 99 Rest of Latin America: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)

List of Figures:

  • Figure 1. Global Prostate Cancer Biomarker Market, 2020-2034 (USD Billion)
  • Figure 2. Integrated Ecosystem
  • Figure 3. Research Methodology: Top-Down & Bottom-Up Price
  • Figure 4. Market by Geography
  • Figure 5. Porter's Five Forces
  • Figure 6. Market by Type
  • Figure 7. Global Prostate Cancer Biomarker Market, by Type, 2024 & 2034 (USD Billion)
  • Figure 8. Market by Application
  • Figure 9. Global Prostate Cancer Biomarker Market, by Application, 2024 & 2034 (USD Billion)
  • Figure 10. Market by End Use
  • Figure 11. Global Prostate Cancer Biomarker Market, by End Use, 2024 & 2034 (USD Billion)